SOLUTIONS with/in/sight: Anchor Management
Immune engineers Darrell Irvine and K. Dane Wittrup join Ankyra Therapeutics CEO Howard Kaufman to discuss the evolution of a convergent bench-to-bedside collaboration that uses localized cytokine therapy to awaken a powerful immune response against solid tumors. The company’s anchored immunotherapy approach grew directly out of two independent Koch Institute research projects and is expected to begin clinical trials in 2023. Immunologist Stefani Spranger provides an introduction to cancer immunotherapy. The program concludes with a dessert reception in the Koch Institute Public Galleries.
Unless otherwise specifically stated in relation to each and any of the events listed on this page, the MLSC does not host or sponsor these events. The MLSC has no oversight or responsibility for the venue, content or host-organization related to these events. The MLSC has no affiliation with the organizations listing events or with the events, and provides this content and information as a convenience to visitors to the MLSC website.